Predictive factors and virological response to interferon treatment in children with chronic hepatitis B

References

• Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318–25.
   Google Scholar
• Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990;323: 295–301.
   Google Scholar
• Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996;334:1422–7.
   Google Scholar
• van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, et al. Long-term follow-up of alphainterferon treatment of patients with chronic hepatitis B. Hepatology 2004;3:804–10.
   Google Scholar
• Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alpha treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139–45.
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Jara P, Crivellaro C, Hierro L, Cadrobbi P, Frauca E, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-y observation period. J Hepatol 1998;29:184–90.
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988;8:1130–3.
   PubMedGoogle Scholar
• Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Interferon alpha therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988–95.
   PubMed Web of Science ®Google Scholar
• Vajro P, Tedesco M, Fontanella A, De Vincenzo A, Vecchione R, Ammendola R, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996;15: 223–31.
   Google Scholar
• Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children [see comments]. J Pediatr Gastroenterol Nutr 1999;29:163–70.
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Wirth S, Crivellaro C, Alberti A, Martine U, de Moliner L. Long-term persistence of hepatitis B virus DNA in the serum of children with chronic hepatitis B after hepatitis B e antigen to antibody seroconversion. J Pediatr Gastroenterol Nutr 1996;22:270–4.
   Google Scholar
• Nagata I, Colucci G, Gregorio GV, Cheeseman P, Williams R, Mieli-Vergani G, Vergani D. The role of HBV DNA quantitative PCR in monitoring the response to interferon treatment in chronic hepatitis B virus infection. J Hepatol 1999;30:965–9.
   Google Scholar
• Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–5.
   PubMed Web of Science ®Google Scholar
• Krogsgaard K, Marcellin P, Trepo C, Berthelot P, Sanchez-Tapias JM, Bassendine M, et al. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. J Hepatol 1996;25:803–13.
   Google Scholar
• Lai CL, Lin HJ, Lau JN, Flok AS, Wu PC, Chung HT, et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991;78:155–63.
   PubMedGoogle Scholar
• Niederau C, Heintges T, Niederau M, Stremmel W, Strohmeyer G. Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. Eur J Med 1992;1:396–402.
   Google Scholar
• Chen M, Sallberg M, Sonnerborg A, Jin L, Birkett A, Peterson D, et al. Human and murine antibody recognition is focused on the ATPase/helicase, but not the protease domain of the hepatitis C virus non-structural 3 protein. Hepatology 1998;28:219–24.
   PubMedGoogle Scholar
• Sallberg M, Zhang ZX, Chen M, Jin L, Birkett A, Peterson DL, Milich DR. Immunogenicity and antigenicity of the ATPase/helicase domain of the hepatitis C virus nonstructural 3 protein. J Gen Virol 1996;77: 2721–8.
   Google Scholar
• Colloredo G, Bellati G, Leandro G, Colombatto P, Rho A, Bissoli F, et al. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new ‘grey-zone’ for the evaluation of ‘borderline’ values. J Hepatol 1996;25:644–8.
   PubMedGoogle Scholar
• Lindh M, Horal P, Dhillon AP, Furuta Y, Norkrans G. Hepatitis B virus carriers without precore mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology 1996;24:494–501.
   Google Scholar
• Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus: largescale analysis using a new genotyping method. J Infect Dis 1997;175: 1285–93.
   Google Scholar
• Lindh M, Hannoun C, Horal P, Krogsgaard K. Virological response to interferon therapy of chronic hepatitis B as measured by a highly sensitive assay. J Viral Hepat 2001;8:349–57.
   PubMedGoogle Scholar
• Newcombe RG, Altman DG. Proportions and their differences, 2nd edn. Bristol: BMJ Books; 2000.
   Google Scholar
• Lok AS, Ghany MG, Watson G, Ayola B. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepat 1998;5:171–8.
   PubMedGoogle Scholar
• Janssen HL, Gerken G, Carreno V, Marcellin P, Naoumov NV, Craxi A, et al. Interferon alpha for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EURO-HEP). Hepatology 1999;30:238–43.
   PubMed Web of Science ®Google Scholar
• Sokal EM, Wirth S, Goyens P, Depreterre A, Cornu C. Interferon alpha-2b therapy in children with chronic hepatitis B. Gut 1993;34\(Suppl 2):S87–90.
   Google Scholar
• Chang MH. Hepatitis B: long-term outcome and benefits from mass vaccination in children. Acta Gastroenterol Belg 1998;6:210–3.
   Google Scholar
• EASL International consensus conference on hepatitis B13 14 September, 2002Geneva, Switzerland. Consensus statement. J Hepatol 2003;38:533–40.
   Google Scholar
• Heijtink RA, Janssen HL, Hop WC, Osterhaus AD, Schalm SW. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J Viral Hepat 2000;7:382–6.
   Google Scholar
• Bortolotti F, Bertaggia A, Rude L, Armigliato M, Crivellaro C, Alberti A, et al. IgM antibody to hepatitis B core antigen in children with chronic type B hepatitis. Eur J Pediatr 1987;146:394–7.
   PubMedGoogle Scholar
• Colloredo G, Bellati G, Sonzogni A, Zavaglia C, Fracassetti O, Leandro G, et al. Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B. J Viral Hepat 1999;6:429–34.
   PubMedGoogle Scholar
• Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alphainterferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761–3.
   Google Scholar